4D Molecular Therapeutics (NASDAQ:FDMT) Earns “Sell (D-)” Rating from Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating reiterated by Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

A number of other equities research analysts have also issued reports on FDMT. Bank of America cut their price target on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $40.00 to $15.00 in a report on Monday, January 13th. Morgan Stanley lowered their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, January 13th. Finally, Royal Bank of Canada lowered their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.56.

4D Molecular Therapeutics Stock Up 5.9 %

NASDAQ:FDMT opened at $5.93 on Friday. The stock has a fifty day simple moving average of $5.97 and a 200 day simple moving average of $10.05. The firm has a market capitalization of $274.14 million, a price-to-earnings ratio of -2.08 and a beta of 2.81. 4D Molecular Therapeutics has a 1-year low of $4.43 and a 1-year high of $36.25.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at $40,000. Values First Advisors Inc. bought a new position in 4D Molecular Therapeutics during the third quarter valued at about $57,000. China Universal Asset Management Co. Ltd. lifted its position in shares of 4D Molecular Therapeutics by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after buying an additional 3,922 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $108,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at about $166,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.